The role of maintenance therapy in disseminated testicular cancer

Lawrence Einhorn, S. D. Williams, M. Troner, R. Birch, F. A. Greco

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

We conducted a prospective study of the value of maintenance therapy in disseminated testicular cancer after chemotherapy-induced complete remission or chemotherapy cytoreduction followed by surgical resection of residual teratoma. A group of 171 patients were randomized to treatment consisting of cisplatin, vinblastine, and bleomycin, or these drugs plus doxorubicin. There was no apparent difference between these two induction regimens. Complete remission was achieved in 113 patients (66 per cent), and 19 (11 per cent) were free of disease by surgical resection of residual tumor. Of the 171 who started, 113 were eligible to receive either maintenance doses of vinblastine (58 patients) or no further therapy (55 patients) after remission-induction therapy. There was a 9 per cent relapse rate during maintenance with vinblastine and a 7 per cent relapse rate with no maintenance therapy; the overall relapse rate was 8 per cent (nine of 113). Our data indicate that maintenance therapy is unnecessary in disseminated testicular cancer.

Original languageEnglish
Pages (from-to)727-731
Number of pages5
JournalNew England Journal of Medicine
Volume305
Issue number13
StatePublished - 1981

Fingerprint

Testicular Neoplasms
Vinblastine
Recurrence
Therapeutics
Remission Induction
Drug Therapy
Teratoma
Bleomycin
Residual Neoplasm
Doxorubicin
Cisplatin
Maintenance
Prospective Studies
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Einhorn, L., Williams, S. D., Troner, M., Birch, R., & Greco, F. A. (1981). The role of maintenance therapy in disseminated testicular cancer. New England Journal of Medicine, 305(13), 727-731.

The role of maintenance therapy in disseminated testicular cancer. / Einhorn, Lawrence; Williams, S. D.; Troner, M.; Birch, R.; Greco, F. A.

In: New England Journal of Medicine, Vol. 305, No. 13, 1981, p. 727-731.

Research output: Contribution to journalArticle

Einhorn, L, Williams, SD, Troner, M, Birch, R & Greco, FA 1981, 'The role of maintenance therapy in disseminated testicular cancer', New England Journal of Medicine, vol. 305, no. 13, pp. 727-731.
Einhorn, Lawrence ; Williams, S. D. ; Troner, M. ; Birch, R. ; Greco, F. A. / The role of maintenance therapy in disseminated testicular cancer. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 13. pp. 727-731.
@article{5d83a087de674ae4bbded680d1a6848a,
title = "The role of maintenance therapy in disseminated testicular cancer",
abstract = "We conducted a prospective study of the value of maintenance therapy in disseminated testicular cancer after chemotherapy-induced complete remission or chemotherapy cytoreduction followed by surgical resection of residual teratoma. A group of 171 patients were randomized to treatment consisting of cisplatin, vinblastine, and bleomycin, or these drugs plus doxorubicin. There was no apparent difference between these two induction regimens. Complete remission was achieved in 113 patients (66 per cent), and 19 (11 per cent) were free of disease by surgical resection of residual tumor. Of the 171 who started, 113 were eligible to receive either maintenance doses of vinblastine (58 patients) or no further therapy (55 patients) after remission-induction therapy. There was a 9 per cent relapse rate during maintenance with vinblastine and a 7 per cent relapse rate with no maintenance therapy; the overall relapse rate was 8 per cent (nine of 113). Our data indicate that maintenance therapy is unnecessary in disseminated testicular cancer.",
author = "Lawrence Einhorn and Williams, {S. D.} and M. Troner and R. Birch and Greco, {F. A.}",
year = "1981",
language = "English",
volume = "305",
pages = "727--731",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

TY - JOUR

T1 - The role of maintenance therapy in disseminated testicular cancer

AU - Einhorn, Lawrence

AU - Williams, S. D.

AU - Troner, M.

AU - Birch, R.

AU - Greco, F. A.

PY - 1981

Y1 - 1981

N2 - We conducted a prospective study of the value of maintenance therapy in disseminated testicular cancer after chemotherapy-induced complete remission or chemotherapy cytoreduction followed by surgical resection of residual teratoma. A group of 171 patients were randomized to treatment consisting of cisplatin, vinblastine, and bleomycin, or these drugs plus doxorubicin. There was no apparent difference between these two induction regimens. Complete remission was achieved in 113 patients (66 per cent), and 19 (11 per cent) were free of disease by surgical resection of residual tumor. Of the 171 who started, 113 were eligible to receive either maintenance doses of vinblastine (58 patients) or no further therapy (55 patients) after remission-induction therapy. There was a 9 per cent relapse rate during maintenance with vinblastine and a 7 per cent relapse rate with no maintenance therapy; the overall relapse rate was 8 per cent (nine of 113). Our data indicate that maintenance therapy is unnecessary in disseminated testicular cancer.

AB - We conducted a prospective study of the value of maintenance therapy in disseminated testicular cancer after chemotherapy-induced complete remission or chemotherapy cytoreduction followed by surgical resection of residual teratoma. A group of 171 patients were randomized to treatment consisting of cisplatin, vinblastine, and bleomycin, or these drugs plus doxorubicin. There was no apparent difference between these two induction regimens. Complete remission was achieved in 113 patients (66 per cent), and 19 (11 per cent) were free of disease by surgical resection of residual tumor. Of the 171 who started, 113 were eligible to receive either maintenance doses of vinblastine (58 patients) or no further therapy (55 patients) after remission-induction therapy. There was a 9 per cent relapse rate during maintenance with vinblastine and a 7 per cent relapse rate with no maintenance therapy; the overall relapse rate was 8 per cent (nine of 113). Our data indicate that maintenance therapy is unnecessary in disseminated testicular cancer.

UR - http://www.scopus.com/inward/record.url?scp=0019494152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019494152&partnerID=8YFLogxK

M3 - Article

VL - 305

SP - 727

EP - 731

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -